SCHEMBL6729296

SCHEMBL6729296

NS(=O)(=O)c1ccc(-c2c(-c3cccc(F)c3)noc2C(F)(F)F)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.47
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
PTGS1 P23219 5/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
CYP11B2 P19099 1/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA4 P22748 2/20 0.36
CA7 P43166 2/20 0.36
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
ALDH1A1 P00352 1/20 0.35
PTPN1 P18031 1/20 0.35
CA12 O43570 1/20 0.35
MT-CO2 P00403 1/20 0.35
LMNA P02545 1/20 0.35
CA3 P07451 1/20 0.35
ADRB2 P07550 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6721348 0.90 PTGS2 (0.47) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6718530 0.90 PTGS2 (0.59) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6721417 0.90 PTGS2 (0.50) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6726419 0.89 PTGS2 (0.46) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6722747 0.89 PTGS2 (0.46) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6725321 0.89 PTGS2 (0.48) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6723316 0.89 PTGS2 (0.56) PTGS2ESR1ESR2PTGS1CYP11B2
SCHEMBL6726040 0.89 PTGS2 (0.48) PTGS2ESR1ESR2PTGS1F2
SCHEMBL6722713 0.89 PTGS2 (0.60) PTGS2ESR1ESR2PTGS1CA1
SCHEMBL6719315 0.88 PTGS2 (0.48) PTGS2ESR1ESR2PTGS1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885ESR1 1770/4885ESR2 176/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885ESR1 1900/4885ESR2 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.